TEM

ANALYST NOTE: TEM (Tempus AI, Inc.) Date: 2026-06-20 Analyst: StoryStocks-Native Equity Research

1. Structural Readiness

Current State: Forming

• Conservative Entry: Not yet actionable (requires breakout confirmation).
• Aggressive Entry: $46.92 (Pre-breakout / forming entry zone).
• Breakout Level: $104.32 (The resistance threshold that must be cleared to confirm the setup).
• Current Extension: None (Price is within the base range, not extended above the breakout).
• Volatility Context: Current ATR is 7.2%, categorized as very_high. This elevated volatility suggests significant price swings are occurring within the base, requiring careful position sizing if entering aggressively.

2. Thesis Layer

Primary Secular Theme: Biotech & GLP-1 → Diagnostics (Tier Direct, High Confidence). Thesis Weighting: Tempus AI is a direct beneficiary of the secular shift toward precision medicine and AI-driven diagnostics. The company sits at the intersection of the "Biotech" and "AI" narratives, specifically within the "Diagnostics" sub-sector.

• Direct Exposure: The company's core revenue engine is the sale of comprehensive genetic testing and the licensing of structured healthcare data.
• Secondary Tailwinds: The acquisition of Paige.AI (digital pathology) and Ambry Genetics (hereditary cancer screening) expands the company's footprint into adjacent high-growth diagnostic verticals, reinforcing its position as a comprehensive data and testing platform rather than a single-product vendor.

3. Business Analysis

Business Model & Industry: Tempus AI operates in the Technology sector, specifically within the Healthcare Technology and Diagnostics industry. The company generates revenue through three primary streams:

• Diagnostics: Selling comprehensive genetic testing to physicians and academic institutions.
• Data & Applications: Licensing structured clinical and molecular data to third parties (pharma, biotech) and providing software tools.
• Clinical Trials: Matching patients to clinical trials.

Operational Evidence (as of 2026-06-20):

• Revenue Visibility: Management reported in the May 5, 2026 earnings transcript that the company achieved its third straight quarter of bookings north of $100 million, with Total Contract Value (TCV) rising and visibility in the "Data and Apps" business at its best level in some time.
• Guidance: On May 5, 2026, management raised full-year guidance to a range of $1.59 billion to $1.6 billion in revenue, with adjusted EBITDA expected to be approximately $65 million.
• Growth Drivers: The Oncology business reported unit growth of 28%, driven by strong performance in solid tumors, liquid biopsies, and MRD (Minimal Residual Disease) volume.
• Strategic Expansion: The company recently added Merck as a major strategic collaborator and expanded its relationship with Gilead.
• M&A Integration: The company has successfully integrated key acquisitions to broaden its portfolio:
• Paige.AI (Acquired Aug 2025): An AI company specializing in digital pathology.
• Ambry Genetics (Acquired Feb 2025): A leader in hereditary cancer screening, now the supplier for Tempus|xG.
• OneOme (Acquired Nov 2025): Enhanced pharmacogenetics capabilities (e.g., DPYD testing).
• Data Moat: As of the February 2026 filing, the company has amassed approximately 1.4 billion documents across 8.6 million de-identified patient records, including 1.6 billion pages of clinical text used to train its large language models.
• Capital Structure: On May 5, 2026, the company completed a private offering of $750 million in 0.75% Convertible Senior Notes due 2030, netting $725.7 million to fund growth and operations.

4. Archetype and Conviction

Archetype: Growth Leader. Rationale: The company fits the "Growth Leader" archetype due to its double-digit unit growth (28% in Oncology), expanding total contract value, and the successful integration of multiple high-value acquisitions that have broadened its addressable market. The transition from pure diagnostics to a data-and-apps platform suggests a margin inflection potential as the high-margin data licensing business scales.

Conviction Stack:

• Thesis Strength: High. The secular tailwinds for AI in healthcare and precision diagnostics are robust, and Tempus is a primary infrastructure play.
• Evidence Quality: Strong. The evidence base is rich with specific financial metrics (bookings, TCV, EBITDA guidance) and strategic milestones (M&A, partnerships) recorded as of May 2026.
• Structural Quality: Moderate to High. The "forming" coil indicates a healthy consolidation phase, but the very_high ATR (7.2%) introduces execution risk. The stock is volatile, and the breakout level ($104.32) is significantly higher than the current price ($50.84), implying a substantial move is required to confirm the setup.
• Rerating Potential: Significant. If the company can sustain the mid-teens growth rate management expects for the second half of the year and successfully monetize the Paige and Ambry integrations, the market may re-rate the stock from a "growth at any cost" to a "profitable growth" multiple.

5. Invalidation, Strengthening, and Gaps

Invalidation Triggers:

• Fundamental: A failure to maintain bookings north of $100 million per quarter or a significant miss on the $1.59–$1.6 billion revenue guidance would undermine the growth narrative.

Strengthening Triggers:

• Technical: A sustained close above $104.32 would confirm the breakout, transitioning the setup to "confirmed-active."
• Fundamental: Confirmation of the "mid-teens" growth rate in the second half of the year and successful FDA approvals for the products mentioned (referenced as having ~$500 incremental ASP lift potential).

Evidence Gaps:

• No Missing Evidence: The evidence base is complete for the stated date.
• Observation: While the guidance is raised, the path to profitability (EBITDA of $65M) is still relatively narrow compared to the revenue scale, suggesting the company remains in a high-investment growth phase. The specific timeline for the $500 ASP lift is noted as "next year or 2," which is a management expectation rather than a guaranteed near-term catalyst.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Third straight quarter of bookings >$100M; Raised full-year revenue guidance to $1.59-$1.6B; Successful integration of Paige.AI and Ambry Genetics; Strong 28% unit growth in Oncology. Key risks: Very high current ATR (7.2%) indicating elevated volatility and potential for false breakouts; Breakout level ($104.32) is double the current price ($50.84), requiring a massive move; Dependence on continued high growth to justify valuation; Convertible note dilution risk over the long term. Sizing hint: Position size should be reduced relative to a confirmed breakout setup due to the "forming" state and very high volatility; treat as a high-risk/high-reward satellite holding. Expected path: Management expects bookings to remain strong and growth to return to mid-teens in H2; the stock likely needs to consolidate near current levels or test the $42.62 support before attempting a move toward the $104.32 breakout zone. Expected horizon: 6 to 12 months for the structural setup to resolve (either breakout or invalidation). Failure mode to watch: A daily close below $42.62, which would signal the coil structure has failed and the thesis is currently broken.